Mitochondrial Ageing: Where NAD+, MOTS-c and SS-31 Actually Sit in the Research

Mitochondrial decline is not one process. It is at least three, and they fail independently: the signal that tells a cell to build more mitochondrial capacity, the physical structure that holds the energy machinery together, and the coenzyme that every one of those processes spends. The three compounds most often grouped under "mitochondrial support" happen to line up against those three failure points, which is the reason they are grouped rather than treated as alternatives.

The more useful thing this article can do is say how much evidence sits behind each one, because the answer differs sharply between them.

MOTS-c: the signal

MOTS-c is a peptide encoded in mitochondrial DNA rather than nuclear DNA, which was itself the notable part when it was described in 2015. The original work reported that it acts through AMPK signalling, the pathway a cell uses to register energy stress and respond by increasing metabolic capacity. In mouse models it reduced diet-induced obesity and insulin resistance.

Later work in diet-induced obese mice used an untargeted metabolomics approach and reported reductions in sphingolipid, monoacylglycerol and dicarboxylate metabolism, pathways that run in the opposite direction in obesity and type 2 diabetes models.

The honest summary: the mechanism is specific and well described, and the metabolic findings are consistent. They are also, to date, largely findings in animals. MOTS-c is described in the literature as an exercise mimetic, and that phrase is doing a lot of work in popular summaries that the underlying papers do not support.

SS-31: the structure

SS-31, also known as elamipretide, concentrates in the inner mitochondrial membrane and interacts with cardiolipin, the phospholipid that holds the components of the electron transport chain in the right physical arrangement. When cardiolipin is disorganised, the machinery leaks energy regardless of how much fuel or signal is available. This is a structural target rather than a signalling one.

SS-31 is also the only compound in this group with a completed phase 3 trial, and the result deserves to be reported accurately rather than skipped.

MMPOWER-3 randomised 218 people with genetically confirmed primary mitochondrial myopathy to 40 mg per day subcutaneously or placebo for 24 weeks. It did not meet either primary endpoint. The difference in six-minute walk distance was −3.2 metres against placebo, and the fatigue score difference was not significant either. Treatment was well tolerated.

This is not a footnote. A negative phase 3 in the disease population where the mechanism should matter most is the single most informative piece of evidence available about this compound, and any summary that omits it is selling something. What the trial does establish is a tolerability profile at a known dose over 24 weeks, which is more than can be said for most compounds in this category.

NAD+: the fuel, and a distinction that matters

NAD+ is a coenzyme spent by both of the processes above, and its decline with age is among the better-replicated findings in the field. The complication is not whether NAD+ matters. It is how the human evidence was generated.

Most controlled human data concerns oral NAD+ precursors rather than NAD+ itself. In an eight-week randomised, double-blind, placebo-controlled trial in overweight but otherwise healthy adults, oral nicotinamide riboside at 100, 300 and 1000 mg per day raised whole-blood NAD+ by 22%, 51% and 142% respectively, dose-dependently, with adverse events comparable to placebo.

That trial demonstrates that blood NAD+ can be raised, by that route, at those doses, and that doing so was well tolerated. It does not demonstrate a clinical outcome, and it does not transfer to injected NAD+, which is a different molecule taking a different route into the body. The distinction is routinely collapsed in marketing copy. It should not be.

It is also worth noting that the trial was funded by the manufacturer of the ingredient tested, which the paper discloses. That does not invalidate the result, but it is the sort of thing a reader is entitled to know without having to open the paper.

Why they are studied together

The argument for examining the three in parallel is about coverage, not synergy. Each addresses a decline documented separately in the ageing literature, and no published trial has tested the three together. Any claim that the combination outperforms the parts is an extrapolation, not a finding.

What would change this picture

For MOTS-c, controlled human trials. For SS-31, a positive result in some population, since the phase 3 attempt in the most mechanistically obvious one failed. For NAD+, human data on the injected form rather than oral precursors. None of those exist yet in the published record, and this article will be worth rewriting when they do.

Research-use-only

This article summarises publicly available research literature. These compounds are supplied for research purposes only, are not approved for human or veterinary use, and nothing here constitutes medical advice or a dosing recommendation.